The rationale for use of standard heart failure medications such as angiotensin-converting enzyme (ACE) inhibitors and beta-blockers is largely extrapolated from the adult experience with limited pediatric data, especially specific to pediatric patients with CCM. The gene discussed is ACE; the disease is cerebral cavernous malformation.